ClinicalTrials.gg

Program

Lomustine

Also written as “Lomustine (CCNU)”, “L19TNF and CCNU” and “nab-sirolimus + lomustine”.

Its studies are mostly in Glioblastoma · Glioma, led by 8 companies.

Furthest: phase 3, since Jul 30, 20259 company-led studies, 1 open or runningNext primary completion: Jan 30, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Philogen21 open or runningphase 2since Jul 30, 2025Feb 24, 2022Jan 30, 2029phase 2 · NCT07120984
Aadi Bioscience10 open or runningphase 2since Mar 5, 2018Mar 5, 2018none ahead
Bristol-Myers Squibb10 open or runningphase 2since Jul 28, 2009Jul 28, 2009none ahead
Eli Lilly10 open or runningphase 2since Apr 19, 2012Apr 19, 2012none ahead
Hoffmann-La Roche10 open or runningphase 2since May 21, 2013May 21, 2013none ahead
Karyopharm Therapeutics10 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Novartis10 open or runningphase 1since Aug 20, 2013Aug 20, 2013none ahead
Pfizer10 open or runningphase 3since Sep 12, 2003Sep 12, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2003First study: phase 3 study in GlioblastomaNew to PfizerPfizer · NCT00068952 · 118 enrolled · United States, Australia, Austria and more
  2. Jul 28, 2009Bristol-Myers Squibb's first study: phase 2 study in GlioblastomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00948389 · 28 enrolled · France, Italy, Netherlands and more
  3. Apr 19, 2012Eli Lilly's first study: phase 2 study in GlioblastomaNew to Eli LillyEli Lilly · NCT01582269 · 158 enrolled · United States, Australia, Belgium and more
  4. May 21, 2013Hoffmann-La Roche's first study: phase 2 study in GlioblastomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01860638 · 296 enrolled · Austria, Bulgaria, Canada and more
  5. Aug 20, 2013Novartis's first study: phase 1 study in GlioblastomaNew to NovartisNovartis · NCT01934361 · 35 enrolled · United States, Australia, Belgium and more
  6. Mar 5, 2018Aadi Bioscience's first study: phase 2 study in High Grade Recurrent Glioma and Newly Diagnosed GlioblastomaNew to Aadi BioscienceAadi Bioscience · NCT03463265 · 62 enrolled · United States
  7. Jun 1, 2020Karyopharm Therapeutics's first study: phase 2 study in GlioblastomaNew to Karyopharm TherapeuticsKaryopharm Therapeutics · NCT04421378 · 74 enrolled · United States, Canada
  8. Feb 24, 2022Philogen's first study: phase 1 study in GlioblastomaNew to PhilogenPhilogen · NCT05304663
  9. Jul 30, 2025Phase 2 study in GliomaPhilogen · NCT07120984 · 52 planned

Ahead

  1. Jan 30, 2029Primary completion: phase 2 study in GliomaPhilogen · NCT07120984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07120984Glioma2Not yet recruitingPhilogenJan 30, 202952
NCT05304663Glioblastoma1WithdrawnPhilogenDec 31, 20240
NCT04421378Glioblastoma · United States, Canada2TerminatedKaryopharm TherapeuticsJul 3, 202374
NCT03463265High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma · United States2CompletedAadi BioscienceAug 26, 202262
NCT01934361Glioblastoma · United States, Australia, Belgium and more1CompletedNovartisJul 7, 201635
NCT01860638Glioblastoma · Austria, Bulgaria, Canada and more2CompletedHoffmann-La RocheJan 13, 2017296
NCT01582269Glioblastoma · United States, Australia, Belgium and more2CompletedEli LillyJul 26, 2014158
NCT00948389Glioblastoma · France, Italy, Netherlands and more2TerminatedBristol-Myers SquibbMay 201128
NCT00068952Glioblastoma · United States, Australia, Austria and more3CompletedPfizer118

How it is read

Names in the registry

  • “Lomustine”, 4 entries
  • “Lomustine (CCNU)”, 2 entries
  • “L19TNF and CCNU”, 1 entry
  • “nab-sirolimus + lomustine”, 1 entry
  • “lomustine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.